Evidence map›Paper›PMID 30229477›Full record

ArticleMolecular biology reports2018

The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.

Abeer A Bahnassy, Magdy M Saber, Mohamed G Mahmoud, Mona S Abdellateif, Mohamed Abd El-Mooti Samra, Rafaat M Abd El-Fatah, Abdel-Rahman N Zekri, Salem E Salem

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Abeer A BahnassyTissue Culture and Cytogenetics Unit, Pathology Department, National Cancer Institute, Cairo University, 1 Fom El-Khalig Street, Cairo, Egypt. chaya2000@hotmail.com.ORCID http://orcid.org/0000-0001-5454-6576
Magdy M SaberDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Mohamed G MahmoudDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Mona S AbdellateifMedical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Mohamed Abd El-Mooti SamraDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Rafaat M Abd El-FatahDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Abdel-Rahman N ZekriMolecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Salem E SalemDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Cairo University · EG

Funding

National Cancer Institute, Cairo University 158/2010
6 · The paper itself

Abstract

The aim of the current study was to assess the prognostic value of circulating tumor cells (CTCs) and their related markers at different points of chemotherapy regimens in metastatic breast cancer (MBC) patients. The impact of CTCs on progression free survival (PFS) and overall survival (OS) rates were also assessed. Peripheral blood samples were obtained from 66 female patients with MBC at different time intervals for evaluation of CTCs by flow cytometry (FC). cytokeratin 19 (CK19), mammaglobin, prolactin inducible peptide (PIP), aldehyde dehydrogenase 1 (ALDH1) and human chorionic gonadotropin (hCG) were also assessed by qRT-PCR. Analysis of different CTC levels (at 4, 5, and 6 cells/7 ml), showed statistically significant values at 4 cells/7 ml blood. The presence of baseline CTCs < 4 cells/7 ml, associated significantly with higher PFS (P value = 0.03). Patients showing a decrease in the CTCs level after treatment had significantly prolonged median PFS and OS rates compared to those whose CTCs level increased (P = 0.007 and P = 0.014; respectively). Mammaglobin, CK19, PIP, ALDH1 and hCG expression did not affect PFS or OS. However, patients with CTCs ≥ 4 at diagnosis had higher rates of progression compared to those with CTCs < 4 (1.9 times, P = 0.07), and who metastasized before 4 years showed a worse decrease outcomes (they were 2.4 time more progressed than those who metastasized after 4 years; P = 0.029). CTCs could be an independent prognostic and predictive biomarker for MBC patients' outcomes. Although none of the assessed genes (mammaglobin, CK19, PIP, ALDH1 and hCG) showed correlation with PFS or OS rates, further studies on a larger number of patients are required to validate the current results.

Indexed as

AdultAldehyde Dehydrogenase 1 FamilyBiomarkers, TumorBreast NeoplasmsCarrier ProteinsChorionic GonadotropinDisease-Free SurvivalDisease ProgressionFemaleGlycoproteinsHumansIsoenzymesKeratin-19Mammaglobin AMembrane Transport ProteinsMiddle AgedAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorCarrier ProteinsChorionic GonadotropinGlycoproteinsIsoenzymesKeratin-19KRT19 protein, humanMammaglobin AMembrane Transport ProteinsPIP protein, humanRetinal DehydrogenaseSCGB2A2 protein, humanALDH1CK19CTCshCGMammaglobinMBCPIP

Identifiers

PMID30229477
OpenAlexW2889653030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.